Adults with obesity treated with semaglutide 2.4 mg achieved a...
- Written by LATEST ASIANET NEWS RELEASES
- Published in Asia Net
BAGSVÆRD, Denmark, March 24, 2021 /PRNewswire-AsiaNet / -- Data presented at ENDO 2021 demonstrate clinically relevant weight loss, without weight regain, in people treated with semaglutide 2.4 mg vs placebo in combination with lifestyle intervention. New results from the STEP phase 3a clinical tria...
Authors: LATEST ASIANET NEWS RELEASES